reports
- Md. Asrarul Haque
The ACME Laboratories Ltd: 1 director bought
A director at The ACME Laboratories Ltd bought 69,500 shares at 0.000BDT and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
- Tanay Roy
ACME Laboratories: Q3 FY20 earnings decline by c4% yoy despite c17% yo...
Contribution from the new projects generated c17% yoy revenue growth. The new projects, which ACMELAB pursued for the past three years (FY17-FY19), started contributing to the revenue from 1Q FY20 (Jul-Sep 2019). During the first half of FY20, the company generated 14.5% yoy top-line growth on an average. With c17% yoy top-line growth in Q3 FY20, ACMELAB’s 9M FY20 yoy revenue growth stood at 15.4%. Earnings declined by c4% yoy due to increase in opex, finance expenses and effective tax rate. ....
- Tanay Roy
Bangladesh pharmaceuticals: Unique sales trend, rate cap lessen Covid-...
The long holiday ended; business activities cautiously re-opened on 31 May. The 66 days of holiday, which started in late March, comprised 38 days of general holiday (ie lockdowns), 20 weekends, and 8 public holidays. Since Bangladesh identified the first Covid-19 patient on 8 March, it has reported 52,445 confirmed cases, 709 deaths, and 11,120 recoveries till 2 June 2020. Bangladesh. The stock market, which remained closed during the holidays because of the pandemic and transition towards a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.